Abstract
Pioneering studies by Eshbach[1][1] demonstrated the effectiveness of treating the anemia of ESRD with erythropoietin-stimulating agents (ESAs). These results led to more aggressive treatment of anemia in an effort to improve quality of life and survival for dialysis and predialysis patients.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have